Biopharmaceutical outsourcing services provider PCI Pharma (PCI) has acquired Sherpa Clinical Packaging in a move to strengthen its product offerings to customers.
acquisition
Sherpa is located in San Diego and provides clinical trial materials management services. PCI has stated that the company’s packaging, labelling, distribution, temperature-controlled storage and returns services are highly complementary to its portfolio.
The acquisition of Sherpa gives PCI eight locations across three continents, giving the company an extensive depot network for its customers.
“PCI’s overarching tenet is to provide the industry leading customer experience.” stated Salim Haffar, PCI chief executive officer. “We evaluated the Sherpa business and found they share this passion, which is demonstrated by their impressive growth. Sherpa’s investments in its capabilities, capacity, and talent have contributed to a successful service model. The integration of the Sherpa business with PCI’s global suite of capabilities and strategic locations allows us to continue to provide a best-in-class offering and be an even stronger partner for our customers.”
PCI has been actively growing clinical trial supply business through investment in internal capabilities as well strategic acquisitions.
Last year, PCI acquired Millmount Healthcare, giving it additional commercial and clinical packaging, storage and distribution capacity, as well as a wider EU base of operations to mitigate customer Brexit concerns about supply chain continuity.
More so, in February 2018 PCI acquired Pharmaceutical Packaging Professionals (PPP), giving it access to early phase clinical studies conducted in Australia. Based in Melbourne, the location now serves as PCI’s regional headquarters for the wider Asia Pacific region.